KR20140134333A - 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 - Google Patents

배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20140134333A
KR20140134333A KR1020147029163A KR20147029163A KR20140134333A KR 20140134333 A KR20140134333 A KR 20140134333A KR 1020147029163 A KR1020147029163 A KR 1020147029163A KR 20147029163 A KR20147029163 A KR 20147029163A KR 20140134333 A KR20140134333 A KR 20140134333A
Authority
KR
South Korea
Prior art keywords
hours
release
agent
active ingredient
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147029163A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 딜
Original Assignee
웰즐리 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by 웰즐리 파마슈티컬스 엘엘씨 filed Critical 웰즐리 파마슈티컬스 엘엘씨
Publication of KR20140134333A publication Critical patent/KR20140134333A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147029163A 2012-03-19 2013-03-13 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 Ceased KR20140134333A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
PCT/US2013/030901 WO2013142197A1 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
KR20140134333A true KR20140134333A (ko) 2014-11-21

Family

ID=49223209

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147029163A Ceased KR20140134333A (ko) 2012-03-19 2013-03-13 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
KR1020177002422A Ceased KR20170015537A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법
KR20147024604A Ceased KR20140134284A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법
KR1020187038194A Ceased KR20190003840A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020177002422A Ceased KR20170015537A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법
KR20147024604A Ceased KR20140134284A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법
KR1020187038194A Ceased KR20190003840A (ko) 2012-03-19 2013-03-14 배뇨 빈도를 감소시키기 위한 연장 방출형 제형 및 그 사용 방법

Country Status (15)

Country Link
EP (2) EP2827852A4 (enExample)
JP (5) JP2015510928A (enExample)
KR (4) KR20140134333A (enExample)
CN (4) CN104302284A (enExample)
AU (4) AU2013235518B2 (enExample)
BR (2) BR112014020271A8 (enExample)
CA (2) CA2866853A1 (enExample)
HK (3) HK1204553A1 (enExample)
MX (3) MX2014011128A (enExample)
MY (2) MY174090A (enExample)
NZ (6) NZ714288A (enExample)
RU (3) RU2669565C2 (enExample)
SG (2) SG11201500408VA (enExample)
WO (2) WO2013142197A1 (enExample)
ZA (2) ZA201405862B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
JP2017535567A (ja) * 2014-11-20 2017-11-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2016331871A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296417A (zh) * 1998-02-10 2001-05-23 卫福有限公司 控释制剂
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005526040A (ja) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用
MXPA04012070A (es) * 2002-06-07 2005-03-07 Yamanouchi Pharma Co Ltd Agente terapeutico para vejiga hiperactiva.
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP1792629A4 (en) * 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
BRPI0615432A2 (pt) * 2005-09-02 2011-05-17 Theravida Inc composição farmacêutica, e, uso de compostos
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
CN107789626A (zh) 2018-03-13
BR112014020271A8 (pt) 2017-07-11
ZA201406146B (en) 2016-08-31
MY174090A (en) 2020-03-09
AU2017203139A1 (en) 2017-06-01
MX2014011129A (es) 2015-08-10
JP2015510928A (ja) 2015-04-13
CN104302284A (zh) 2015-01-21
NZ712594A (en) 2016-09-30
WO2013142197A1 (en) 2013-09-26
BR112014020113A2 (enExample) 2017-06-20
RU2599017C2 (ru) 2016-10-10
CN104321056A (zh) 2015-01-28
SG11201500409SA (en) 2015-03-30
CN107157991A (zh) 2017-09-15
CA2866853A1 (en) 2013-07-26
HK1204553A1 (en) 2015-11-27
AU2013235507B2 (en) 2017-03-23
KR20190003840A (ko) 2019-01-09
NZ714288A (en) 2016-12-23
BR112014020271A2 (enExample) 2017-06-20
AU2017203246A1 (en) 2017-06-08
RU2014142025A (ru) 2016-05-10
CA2866755A1 (en) 2013-09-26
NZ628079A (en) 2016-05-27
AU2013235518A2 (en) 2014-10-09
JP2018138602A (ja) 2018-09-06
RU2669565C2 (ru) 2018-10-12
AU2013235518A1 (en) 2014-09-25
KR20170015537A (ko) 2017-02-08
MX2014011128A (es) 2015-08-10
EP2827852A4 (en) 2016-03-02
JP2018024693A (ja) 2018-02-15
EP2827851A1 (en) 2015-01-28
RU2014142066A (ru) 2016-05-10
JP2015510936A (ja) 2015-04-13
SG11201500408VA (en) 2015-03-30
NZ714662A (en) 2016-08-26
KR20140134284A (ko) 2014-11-21
AU2013235507A1 (en) 2014-08-21
HK1243921A1 (zh) 2018-07-27
JP2016172752A (ja) 2016-09-29
BR112014020113A8 (pt) 2017-07-11
EP2827852A1 (en) 2015-01-28
NZ630471A (en) 2016-04-29
RU2016133305A3 (enExample) 2018-12-10
RU2016133305A (ru) 2018-12-10
AU2013235518B2 (en) 2017-03-02
AU2017203139B2 (en) 2018-07-19
EP2827851A4 (en) 2015-10-14
MX2019008817A (es) 2019-09-26
MY175764A (en) 2020-07-08
ZA201405862B (en) 2016-08-31
WO2013142274A1 (en) 2013-09-26
NZ718163A (en) 2017-09-29
HK1251469A1 (zh) 2019-02-01
AU2017203246B2 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AU2017203139B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20140108675A (ko) 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
KR20140108674A (ko) 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
US20180344674A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20180055858A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20180066112A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
KR20180054655A (ko) 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
KR20180066113A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
KR20180094512A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
US20170079964A1 (en) Composition for reducing the frequency of urination, method of making and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180305

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190708

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191007

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190708

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I